The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

Researchers have developed a new gene-editing platform that will enable safer and more effective T cell–based immunotherapies ...

We are investigating so-called anti-CRISPRs: proteins or other molecules that phages use to inhibit CRISPR. A bacterium that has CRISPR might be able to stop a phage from infecting. But if the phage ...

CRISPR Therapeutics could stage a comeback thanks to clinical and commercial progress. There are many promising corporations ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...

This in vivo targeted lipid nanoparticle anti-CD19 CAR-T therapy candidate is currently in Phase 1 development. Additionally, AbbVie will acquire Capstan's proprietary tLNP platform technology ...

RFK Jr. is fighting a two-front war against chronic disease and anti-MAHA partisans by Douglas MacKinnon, opinion contributor - 06/28/25 12:00 PM ET ...

Explore the 10 best anti-inflammatory supplements reviewed by RDs. From joint support to heart health, these expert-approved picks are worth trying in 2025.

Protesters gathered nationwide Wednesday as part of a movement opposing the Trump administration's policies and Project 2025, the controversial conservative presidential wish list. The protests ...

CRISPR Therapeutics ’ CRSP first marketed product is the one-shot gene therapy Casgevy, approved in late 2023 and early 2024 across the United States and Europe for two blood disorder ...